Answers are grounded in this paper and cite their sources.
Background/Objectives: Circulating erythritol has been linked to cardiometabolic disorders, but its association with renal function decline remains unclear. We investigated this association in patients with type 2 diabetes and examined the effects of erythritol on interleukin-6 (IL-6) secretion from tubular cells. Methods: This retrospective study included 217 patients with baseline estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2. Plasma erythritol and IL-6 concentrations were measured. Renal outcomes were defined as an annual change in eGFR < −2.5 mL/min/1.73 m2 and an eGFR reduction > 30%. Multivariable logistic regression analyses were performed. Human renal proximal tubular epithelial cells (RPTECs) were treated with erythritol for 24 h. Results: Median follow-up was 50 months. Plasma erythritol concentrations were positively correlated with cardio-ankle vascular index, total plaque score, and plasma IL-6 concentrations, and inversely correlated with baseline eGFR. Among 196 patients with eGFR ≥ 60 mL/min/1.73 m2, higher erythritol concentrations were independently associated with Criterion 1 after adjustment for age, sex, body mass index, eGFR, and urinary albumin-to-creatinine ratio. Erythritol increased IL-6 secretion from RPTECs at 1 and 10 μmol/L. Conclusions: Plasma erythritol may serve as a functional biomarker and risk marker for subsequent renal function decline in patients with type 2 diabetes and relatively preserved kidney function. Its association with plasma IL-6 concentrations and its effects on RPTEC IL-6 secretion suggest a potential link between erythritol and renal tubular inflammation.
No takes yet. Share an insight, caveat, or question.
Takedani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: